Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of NXT007 versus factor VIII prophylaxis in hemophilia A without inhibitors
CTR20263020Phase 3Active
- Sponsor
- Roche
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zemocimig in hemophilia A, sponsored by Roche. Started Aug 2026; status: active.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20263020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263020.